



## Altimune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

March 20, 2024 at 7:30 AM EDT

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.

Altimune management will host a conference call at 8:30 am E.T. on March 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimune's Investor Relations website at <https://ir.altimmune.com/investors>.

Participants who would like to join the call may register [here](#) to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Investor Contact:

Richard Eisenstadt  
Chief Financial Officer  
Phone: 240-654-1450  
[reisenstadt@altimmune.com](mailto:reisenstadt@altimmune.com)

### Media Contact:

Danielle Cantey  
Inizio Evoke Comms  
Phone: 619-826-4657  
[Danielle.cantey@inizioevoke.com](mailto:Danielle.cantey@inizioevoke.com)



altimmune

Source: Altimune, Inc